| 1. |
- Hochhaus, A, et al.
(författare)
-
Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia.
- 2009
-
Ingår i: Leukemia. - : Springer Science and Business Media LLC. - 1476-5551 .- 0887-6924. ; 23:6, s. 1054-61
-
Tidskriftsartikel (refereegranskat)abstract
- Imatinib mesylate is considered standard of care for first-line treatment of chronic phase chronic myeloid leukemia (CML-CP). In the phase III, randomized, open-label International Randomized Study of Interferon vs STI571 (IRIS) trial, previously untreated CML-CP patients were randomized to imatinib (n=553) or interferon-alpha (IFN) plus cytarabine (n=553). This 6-year update focuses on patients randomized to receive imatinib as first-line therapy for newly diagnosed CML-CP. During the sixth year of study treatment, there were no reports of disease progression to accelerated phase (AP) or blast crisis (BC). The toxicity profile was unchanged. The cumulative best complete cytogenetic response (CCyR) rate was 82%; 63% of all patients randomized to receive imatinib and still on study treatment showed CCyR at last assessment. The estimated event-free survival at 6 years was 83%, and the estimated rate of freedom from progression to AP and BC was 93%. The estimated overall survival was 88% -- or 95% when only CML-related deaths were considered. This 6-year update of IRIS underscores the efficacy and safety of imatinib as first-line therapy for patients with CML.
|
|
| 2. |
|
|
| 3. |
- De Waele, J. J., et al.
(författare)
-
Decompressive laparotomy for abdominal compartment syndrome
- 2016
-
Ingår i: British Journal of Surgery. - : Oxford University Press (OUP). - 0007-1323 .- 1365-2168. ; 103:6, s. 709-715
-
Tidskriftsartikel (refereegranskat)abstract
- Background: The effect of decompressive laparotomy on outcomes in patients with abdominal compartment syndrome has been poorly investigated. The aim of this prospective cohort study was to describe the effect of decompressive laparotomy for abdominal compartment syndrome on organ function and outcomes. Methods: This was a prospective cohort study in adult patients who underwent decompressive laparotomy for abdominal compartment syndrome. The primary endpoints were 28-day and 1-year all-cause mortality. Changes in intra-abdominal pressure (IAP) and organ function, and laparotomy-related morbidity were secondary endpoints. Results: Thirty-three patients were included in the study (20 men). Twenty-seven patients were surgical admissions treated for abdominal conditions. The median (i.q.r.) Acute Physiology And Chronic Health Evaluation (APACHE) II score was 26 (20-32). Median IAP was 23 (21-27) mmHg before decompressive laparotomy, decreasing to 12 (9-15), 13 (8-17), 12 (9-15) and 12 (9-14) mmHg after 2, 6, 24 and 72 h. Decompressive laparotomy significantly improved oxygenation and urinary output. Survivors showed improvement in organ function scores, but non-survivors did not. Fourteen complications related to the procedure developed in eight of the 33 patients. The abdomen could be closed primarily in 18 patients. The overall 28-day mortality rate was 36 per cent (12 of 33), which increased to 55 per cent (18 patients) at 1 year. Non-survivors were no different from survivors, except that they tended to be older and on mechanical ventilation. Conclusion: Decompressive laparotomy reduced IAP and had an immediate effect on organ function. It should be considered in patients with abdominal compartment syndrome.
|
|
| 4. |
- Flodén, Anne, 1957, et al.
(författare)
-
Cross-cultural adaptation and psychometric validation of the Floden ATODAI instrument in the North American context
- 2020
-
Ingår i: Bmc Nursing. - : Springer Science and Business Media LLC. - 1472-6955. ; 19:1
-
Tidskriftsartikel (refereegranskat)abstract
- Background Intensive and critical-care nurses are the key to successful donor management in the critical-care setting. No studies measuring attitudes toward organ donor advocacy existed before 2011, when the 51-item Swedish "Attitudes Toward Organ Donor Advocacy Scale" was developed. The aim of this study was to translate, adapt and establish the psychometric properties of the North American version of the Floden ATODAI (Attitudes Toward Organ Donor Advocacy Instrument) in terms of validity and reliability. Methods A multi-step approach was used: Initial translation; Back-translation; Review and synthesis of these translations;Expert panel(N = 7) rated the prefinal version of the instrument for content validity index (CVI);International panelmade adjustments guided by theexpert panel. Reliability testing with test and retest of the adjusted 46-item version was conducted using intraclass correlation coefficient (ICC), weighted kappa (& x4a1;(Weight)), sign test, and Cronbach's alpha coefficient (alpha), (N = 50); and finally Delphi technique procedure with a preselectedDelphi panel(N = 15). Results The CVI was determined to be greater than the 0.05 significance level. Item level (I-CVI) ranged 0.82-1.0, with a mean of 0.97. Scale level (S-CVI) on the entire instrument was 0.97. Test-retest procedure was performed to estimate stability. In total, 34 of the items had good-to-high ICC. Accepting an ICC of >= 0.70 resulted in a total of 24 items. Homogeneity reliability was estimated by alpha and was calculated for these items where alpha = 0.90. In total, 20 of the items had a substantial or almost perfect & x4a1;(Weight)and 23 showed a moderate & x4a1;(Weight). None of the items showed systematical differences. The Delphi technique procedure was used on the 22 items with ICC < 0.70 resulted in adjustments establishing that consensus was achieved. Conclusions Undertaking this multi-step, cross-cultural adaptation procedure has effectively ensured that the 46-item Floden ATODAI [North American version] produces valid and reliable measurements.
|
|
| 5. |
- Kantarjian, Hagop M, et al.
(författare)
-
Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase.
- 2009
-
Ingår i: Cancer. - : Wiley. - 0008-543X .- 1097-0142. ; 115:3, s. 551-60
-
Tidskriftsartikel (refereegranskat)abstract
- Imatinib mesylate given orally at a daily dose of 400 mg is the standard of care as initial therapy for patients with chronic myeloid leukemia (CML) in chronic phase (CML-CP). Treatment guidelines propose dose escalation based on clinical assessments of disease response.
|
|
| 6. |
|
|
